ERBB2 and colorectal carcinoma: HER2 is overexpressed in 7%–34% of gastric cancer, 13%–20% of breast cancer, 1.9%–14.3% of lung cancer, and 2%–11% of CRC cases (Guarini et al., 2021; Ivanova et al., 2022; Siena et al., 2018).